About IPIF

IPIF is a bi-annual international conference initiated by RDPAC in 2017. It is designed to be a premier and inclusive platform for high-level dialogue and collaboration among international leaders from across the healthcare innovation ecosystem with a shared goal of accelerating world-class innovation in China to better serve patient needs around the world. The IPIF17 in Nanjing brought together more than 500 Chinese and foreign experts from government, industry, academia and non-profit organizations and announced the Declaration for Pharmaceutical Innovation by ten trade associations.

International Pharmaceutical Innovation Forum 2019

Save the date March 26, 2019 for a historic meeting with international leaders to accelerate world-class innovation in China for patients around the world

2019 is an especially important year for healthcare in China.

It marks the 70th anniversary of the founding of the People’s Republic of China; the 10th anniversary of the healthcare reform started in2009; and a crucial milestone in goal-setting for Healthy China 2030.

Hosted by the R&D-based Pharmaceutical Association Committee (RDPAC) and a number of leading Chinese and international partners, the International Pharmaceutical Innovation Forum 2019 (IPIF19) will convene international leaders from across the healthcare innovation ecosystem to discuss the most exciting developments and most pressing topics related to patient centric health.

The forum will also enable a call for joint action to accelerate world-class innovation in China to save and improve patient lives around the world.

Themes

The IPIF19 will focus on 5 major topics. More details about the forum agenda and our esteemed speakers will be released very soon.

Supporting the Healthy China 2030 goals through innovation

Driven by the Healthy China 2030 Plan, China is making rapid advances towards becoming a healthier society and building a healthier economy. One of the key measures is to encourage technological innovation through significant investments in the National Science and Technology Major Project. What are the major outcomes of these national programs and how can they be translated into clinical solutions? To support China achieving the goals for 2030, what further reforms should be taken to remove the biggest barriers for the pharmaceutical and healthcare industries to unlock the value of innovation?

Leading the transformation of China’s pharmaceutical industry

China is now the world’s largest exporter of API (active pharmaceutical ingredients) and the third largest generic drug market. To move up the global value chain, China has developed a series of policies to guide and advance the upgrading of its pharmaceutical industry with special focus on innovation and high-quality. To ensure a smooth and successful industrial transformation, what are the most important lessons China should learn from its own development and from other developed economies? What are the critical steps China should take to build a favorable environment and incentivize R&D based international and domestic pharmaceutical companies?

Accelerating world-class innovation in China

China has quickly become and emerging investment hub for healthcare innovation, with experts predicting that some of the next world-class innovations to improve patient lives will come from this market. What are realistic assessments, constructive suggestions and an actionable roadmap for China to become a truly global center for world-class innovation? What role should the government and market forces play to foster high-quality investment, efficient collaboration and productive innovation activities?

Driving institutional innovation for patients

After 70 years of national commitment to public health and 10 years of reforms to the healthcare system, China has made the remarkable achievement of providing basic healthcare to its citizens by deploying the world’s largest medical and health security system. The biggest challenge for the next stage of reform is to provide timely, high-quality and innovative healthcare to an aging population with a better balance between accessibility and affordability. What can China do to ensure the best interests of patients are incorporated into the policy making process?

Shaping the future of digital health innovation

The 4th industrial revolution is fostering disruptive technology innovation that will profoundly change traditional industries. While the world-leading pharmaceutical companies are incorporating digital transformation into their business strategy, the most successful and innovative tech companies are also expanding their business into the healthcare sector. How can pharmaceutical and tech companies work together to shape the future of digital health? Will China become a global leader in intelligent healthcare solutions?

Our
Partners

For sponsorship please contact: ceciliawang@rdpac.org

Copyright © 2011 RDPAC.org All Rights Reserved 京ICP备14020472号-1 京公网安备11010502025687